Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Inclusion Criteria: * Patients with histologically confirmed breast cancer scheduled to receive chemotherapy with doxorubicin and cyclophosphamide (adjuvant or neoadjuvant) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Projected life expectancy of at least 3 months * Provision of informed consent prior to any study-related procedures * Negative pregnancy test for women of childbearing potential * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000 cells/mm\^3 * Hemoglobin \>= 9.0g/dL * Serum creatinine =\< 1.5 mg/dl * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 X upper limit of normal (ULN) * Alkaline phosphatase =\< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =\< upper limit of normal an alkaline phosphatase =\< 5 ULN will be allowed * Serum bilirubin =\< 1.0 mg/dL * No other concomitant therapy directed at the cancer is allowed Exclusion Criteria: * Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone * Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, or corticosteroids) within 72 hours prior to day 1 of the study * Use of anticoagulant agent (Warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, or Warfant) * An episode of vomiting or retching within 24 hours before the start of the initial treatment with chemotherapy * Severe concurrent illness other than neoplasia * Gastrointestinal obstruction or an active peptic ulcer * Patients who are pregnant or breast feeding because aprepitant may be harmful to the developing fetus and newborn